Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
Background: * The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer. Objectives: * To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer. * To establish a repository of genetic information for future studies of these differences and their relation to lung cancer. Eligibility: * Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute. Design: * After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential. * Approximately half a tablespoon of blood will be drawn. * Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study * Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 9, 2019 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- National Cancer Institute (NCI)
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Patients 18 years of age and older are eligible. 2. Histologic diagnosis of primary lung carcinoma. For non small cell lung cancer, patients can be stage I to IV, and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy). For small cell lung cancer, patients can be limited or extensive stage and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy). 3. Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to this protocol. 4. Patients with a current diagnosis of or a prior history of other cancers may be included onto this protocol. 5. Patients may have either normal organ function or impaired organ function.
1\. Children will not be eligible.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 9, 2019. Always confirm current availability with the study team.